Head to Head Analysis: West Pharmaceutical Services (NYSE:WST) versus ClearPoint Neuro (NASDAQ:CLPT)

West Pharmaceutical Services (NYSE:WSTGet Free Report) and ClearPoint Neuro (NASDAQ:CLPTGet Free Report) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, profitability, dividends, institutional ownership, risk and earnings.

Valuation & Earnings

This table compares West Pharmaceutical Services and ClearPoint Neuro”s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
West Pharmaceutical Services $2.95 billion 7.94 $593.40 million $6.74 47.97
ClearPoint Neuro $23.95 million 13.95 -$22.09 million ($0.69) -17.55

West Pharmaceutical Services has higher revenue and earnings than ClearPoint Neuro. ClearPoint Neuro is trading at a lower price-to-earnings ratio than West Pharmaceutical Services, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and recommmendations for West Pharmaceutical Services and ClearPoint Neuro, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
West Pharmaceutical Services 0 1 2 0 2.67
ClearPoint Neuro 0 0 3 0 3.00

West Pharmaceutical Services presently has a consensus target price of $460.33, suggesting a potential upside of 42.38%. ClearPoint Neuro has a consensus target price of $11.33, suggesting a potential downside of 6.41%. Given West Pharmaceutical Services’ higher probable upside, equities research analysts plainly believe West Pharmaceutical Services is more favorable than ClearPoint Neuro.

Institutional & Insider Ownership

93.9% of West Pharmaceutical Services shares are owned by institutional investors. Comparatively, 30.1% of ClearPoint Neuro shares are owned by institutional investors. 0.5% of West Pharmaceutical Services shares are owned by insiders. Comparatively, 6.1% of ClearPoint Neuro shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Risk & Volatility

West Pharmaceutical Services has a beta of 1, meaning that its stock price has a similar volatility profile to the S&P 500.Comparatively, ClearPoint Neuro has a beta of 1.1, meaning that its stock price is 10% more volatile than the S&P 500.

Profitability

This table compares West Pharmaceutical Services and ClearPoint Neuro’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
West Pharmaceutical Services 17.37% 18.41% 13.74%
ClearPoint Neuro -59.64% -62.10% -38.39%

Summary

West Pharmaceutical Services beats ClearPoint Neuro on 9 of the 14 factors compared between the two stocks.

About West Pharmaceutical Services

(Get Free Report)

West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. This segment also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. The company serves pharmaceutical, diagnostic, and medical device companies. It sells and distributes its products through its sales force and distribution network, contract sales agents, and regional distributors. West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania.

About ClearPoint Neuro

(Get Free Report)

ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. It has license and collaboration agreement with Clinical Laserthermia Systems AB; license and research agreement with Koninklijke Philips N.V., UCB Biopharma SRL, and University of California and San Francisco; and development and license agreement with NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.

Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.